Tenaya net loss widens to $43.39 million in Q2 FY26; R&D expenses slip to $16.6 million

Reuters2026/08/05 20:44

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tenaya Therapeutics posted a Q2 net loss of USD 43.4 million, or USD 0.20 a share, widening from USD 23.3 million, or USD 0.14, a year earlier.
R&D expense edged down to USD 16.6 million from USD 17.4 million; G&A expense fell to USD 5.4 million from USD 6.7 million.
Collaboration revenue was USD 1.11 million; the net loss widened mainly due to a USD 21.8 million non-cash impairment tied to early lease termination.
Cash and cash equivalents totaled USD 78.1 million as of June 30; a USD 10 million Alnylam upfront payment helped extend runway through Q3 2027.
Interim data for TN-201 and TN-401 showed improvements in key disease measures; additional data and pivotal-trial regulatory updates are expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051605PRIMZONEFULLFEED9804494) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tenaya net loss widens to $43.39 million in Q2 FY26; R&D expenses slip to $16.6 million

You may also like

Crypto prices